Bioanalysis Zone

Mass Spectrometry vendors see potential growth opportunity in Africa



The Analysis of Global Mass Spectrometry (MS) Market report published earlier this year by consulting firm Frost & Sullivan highlighted untapped potential for Mass Spectrometry vendors in a developing global market.

The report published reveals huge opportunities for MS vendors through mergers and acquisitions with clinical diagnostic companies in the global market, particularly in the Asia-pacific and African regions.

The continual increase in innovations in MS technologies combined with wider applications in both the clinical analysis and life sciences sectors have contributed largely to this global market opportunity.

Frost & Sullivan analyst Krishnan Ramanathan commented: “Currently, North America leads the global market due to the presence of a large number of pharmaceutical and biotechnology companies”.

Recognizing the great potential that lies hidden he added:  “Asia-Pacific holds the greatest potential due to the increasing government funding, business expansion activities by major players, and enhanced adoption by pharmaceutical and life science sectors”.

The report found market proceedings in 2015 were estimated at US$3.02 billion and expected to increase up to US$5.03 billion by 2022.

In addition the MS market is gradually making the shift from traditional systems to high resolution technologies like the Quadrupole-Time of Flight (Q-TOF) MS and MALDI-TOF.

Interestingly, of the two technologies MALDI-TOF sector was identified to significantly increase due to its advantages of high sensitivity, accuracy and enhanced resolution for clinical diagnostic applications.

The combination of a fast developing innovative MS technology sector with miniaturization of these various technologies drive MS vendors to eagerly collaborate with clinical diagnostic companies, expanding the market for novel instruments accurately measuring low trace levels of biomarkers in disease.

Furthermore the growth of outsourcing practices in the established pharmaceutical industry in Europe and North America will allow emerging regions in Asia pacific and Africa to capitalize on outsourcing and grow from this opportunity.

As these developing regions show increasing interest in research and obtain more funding they are expected to steadily climb the ladder in this market.

“The most successful companies are likely to be solution providers rather than stand-alone instrument or software providers,” noted Ramanathan.

“It is critical for advanced technologies to be bundled with service and support, as customers may not have the expertise to operate the high-resolution instruments,” he explained.

Stricter safety regulations in the environmental, food and drink pharmaceutical industries have led to increasing implementation of MS in these sectors.

This, in combination with a rapidly growing clinical diagnostics application and applied testing in developing economies will drive a fast market growth in these emerging regions.

Read the full report in the link here.



Leave A Comment